AraliadiolCAS# 1354638-93-9 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1354638-93-9 | SDF | Download SDF |
| PubChem ID | 124355647 | Appearance | Powder |
| Formula | C15H20O2 | M.Wt | 232.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3S,8R,9Z)-pentadeca-1,9-dien-4,6-diyne-3,8-diol | ||
| SMILES | CCCCCC=CC(C#CC#CC(C=C)O)O | ||
| Standard InChIKey | KZRIUXSFFOWKRO-USJBSMOHSA-N | ||
| Standard InChI | InChI=1S/C15H20O2/c1-3-5-6-7-8-12-15(17)13-10-9-11-14(16)4-2/h4,8,12,14-17H,2-3,5-7H2,1H3/b12-8-/t14-,15+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Araliadiol Dilution Calculator
Araliadiol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.3048 mL | 21.5239 mL | 43.0478 mL | 86.0956 mL | 107.6195 mL |
| 5 mM | 0.861 mL | 4.3048 mL | 8.6096 mL | 17.2191 mL | 21.5239 mL |
| 10 mM | 0.4305 mL | 2.1524 mL | 4.3048 mL | 8.6096 mL | 10.7619 mL |
| 50 mM | 0.0861 mL | 0.4305 mL | 0.861 mL | 1.7219 mL | 2.1524 mL |
| 100 mM | 0.043 mL | 0.2152 mL | 0.4305 mL | 0.861 mL | 1.0762 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Strontium Ranelate
Catalog No.:BCC3858
CAS No.:135459-87-9
- Rehmapicrogenin
Catalog No.:BCN8507
CAS No.:135447-39-1
- 7-O-Prenylscopoletin
Catalog No.:BCN3547
CAS No.:13544-37-1
- JW 480
Catalog No.:BCC6142
CAS No.:1354359-53-7
- trans-Ned 19
Catalog No.:BCC7825
CAS No.:1354235-96-3
- ACT 335827
Catalog No.:BCC6346
CAS No.:1354039-86-3
- KH CB19
Catalog No.:BCC6135
CAS No.:1354037-26-5
- Bullatine A
Catalog No.:BCN2374
CAS No.:1354-84-3
- CX-6258 hydrochloride hydrate
Catalog No.:BCC1505
CAS No.:1353858-99-7
- 8-Prenyldaidzein
Catalog No.:BCN4711
CAS No.:135384-00-8
- 12alpha-Methoxygrandiflorenic acid
Catalog No.:BCN7771
CAS No.:135383-94-7
- 4'-Hydroxyisojasminin
Catalog No.:BCN7383
CAS No.:135378-09-5
- Cabazitaxel intermediate
Catalog No.:BCN7432
CAS No.:1354900-65-4
- CYM 50260
Catalog No.:BCC6259
CAS No.:1355026-60-6
- ML 190
Catalog No.:BCC6308
CAS No.:1355244-02-8
- 2,3-Dihydro-12,13-dihydroxyeuparin
Catalog No.:BCN7189
CAS No.:135531-75-8
- Mutant IDH1-IN-1
Catalog No.:BCC6403
CAS No.:1355326-21-4
- AGI-5198
Catalog No.:BCC2293
CAS No.:1355326-35-0
- Cudraxanthone L
Catalog No.:BCN6187
CAS No.:135541-40-1
- Schisanlignone A
Catalog No.:BCN3628
CAS No.:135557-67-4
- Nav1.7 inhibitor
Catalog No.:BCC4191
CAS No.:1355631-24-1
- Pneumocandin B0
Catalog No.:BCC5436
CAS No.:135575-42-7
- Parsonsianidine
Catalog No.:BCN2109
CAS No.:135601-81-9
- Fmoc-D-His(Trt)-OH
Catalog No.:BCC3504
CAS No.:135610-90-1
Inhibitory effect of human breast cancer cell proliferation via p21-mediated G1 cell cycle arrest by araliadiol isolated from Aralia cordata Thunb.[Pubmed:20717878]
Planta Med. 2011 Jan;77(2):164-8.
A new polyacetylenic compound, Araliadiol, was isolated from the leaves of Aralia cordata Thunb. (Araliaceae). The structure of Araliadiol was determined to be 3( S),8( R)-pentadeca-1,9( Z)-diene-4,6-diyne-3,8-diol by MS, NMR, IR, and UV spectroscopic analysis as well as Mosher ester reaction. Araliadiol displayed a significant inhibitory effect on the growth of a human breast adenocarcinoma cell line (MCF-7), with an IC (50) value for cytotoxicity of 6.41 microg/mL. Cell cycle analysis revealed that the proportion of cells in the G (1) phase of the cell cycle increased in a dose-dependent manner (from 54.7 % to 72.0 %) after 48 h exposure to Araliadiol at dosages ranging from 0 to 80 microM. The results suggest that Araliadiol inhibits cell cycle progression of MCF-7 at the G (1)-S transition. After treatment with Araliadiol, phosphorylation of retinoblastoma protein (Rb) in MCF-7 cells was inhibited, accompanied by a decrease in the levels of cyclin D (3) and cyclin-dependent kinase 4 (cdk4) and an increase in the expression of p21 (WAF-1/Cip1). However, the expression of phosphorylated p53 (Ser15) and Chk2 was not altered in MCF-7 cells. These findings indicate that Araliadiol exhibits its growth-inhibitory effects on MCF-7 cells through downregulation of cdk4 and cyclin D (3), and upregulation of p21 (WAF-1/Cip1) by a p53-independent mechanism.
